CG Oncology (NASDAQ:CGON) Director Sells $350,000.00 in Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total transaction of $350,000.00. Following the sale, the director directly owned 5,000 shares in the company, valued at approximately $350,000. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

CG Oncology Stock Performance

CGON traded up $4.12 during midday trading on Thursday, hitting $72.84. The company had a trading volume of 1,346,084 shares, compared to its average volume of 1,183,786. The company has a market capitalization of $6.42 billion, a PE ratio of -31.26 and a beta of 0.31. CG Oncology, Inc. has a twelve month low of $23.65 and a twelve month high of $75.50. The firm’s 50-day simple moving average is $64.21 and its 200-day simple moving average is $57.70.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The business had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, sell-side analysts anticipate that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.

Analysts Set New Price Targets

CGON has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a report on Monday, April 20th. Royal Bank Of Canada boosted their target price on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of CG Oncology in a research note on Monday, May 18th. Wedbush lifted their price objective on CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Finally, Wolfe Research initiated coverage on shares of CG Oncology in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CG Oncology presently has an average rating of “Moderate Buy” and an average price target of $81.73.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CGON. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CG Oncology during the fourth quarter worth $27,000. NFSG Corp acquired a new position in CG Oncology in the first quarter valued at about $34,000. Comerica Bank lifted its stake in CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares during the period. Fifth Third Bancorp bought a new position in CG Oncology during the first quarter worth about $74,000. Finally, KBC Group NV acquired a new position in shares of CG Oncology during the 1st quarter worth about $78,000. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.